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ABSTRACT  1 
Background  2 
There is limited evidence on whether genotype-tailored advice provides extra benefits in reducing 3 
obesity-related traits than conventional one-size fit all advice.  4 
Objective 5 
The objective was to determine if disclosing information on FTO genotype risk had a bigger effect 6 
on reduction of obesity-related traits in risk carriers than non-risk carriers across different levels 7 
of personalized nutrition.  8 
Design  9 
683 participants (51% women; age range 18-73 y, body mass index ≥25.0 or waist circumference 10 
(WC) >88cm and >102 cm for women and men) from the Food4Me randomized controlled trial 11 
were included in this analysis. Participants were randomized to four interventions arms (Level 0: 12 
Control group, Level 1: “Dietary” group; Level 2: “Phenotype” (BMI, WC, metabolic markers) 13 
group, Level 3: “Genetic” group). FTO (SNP rs9939609) was genotyped at baseline in all 14 
participants but only those randomized to Level 3 were informed about their genotype.  Level 3 15 
participants were stratified into risk (AA/AT) and non-risk carriers (TT) of the FTO gene for these 16 
analyses. Height, weight and WC were self-measured and reported at baseline, months 3 and 6.  17 
Results  18 
Changes in adiposity markers were larger in participants who were informed that they carried the 19 
FTO risk allele (Level 3 AT/AA carriers, n=139) compared with the non-personalized group 20 
(Level 0, n=171), but not compared with the other personalized groups (Level 1, n=153 and Level 21 
2, n=173). Reductions in weight and WC at month 6 were greater for FTO risk carriers (BMI, n= 22 
139 and WC, n=71) compared with non-carriers (BMI, n=47 and WC, n=27) in Level 3 (-2.28 kg 23 
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[-3.06, -1.48] vs. -1.99 kg [-2.19, -0.19], P=0.037; and -4.34 cm [-5.63, -3.08] vs. -1.99 cm, [-4.04, 24 
-0.05] P=0.048, for weight and WC, respectively).  25 
Conclusions 26 
Larger body weight and WC reductions were observed for risk carriers compared with non-risk 27 
carriers of the FTO gene. However, adding genotypic information to the tailored feedback did not 28 
enhance the effect of intervention compared with personalization based on diet or diet and 29 
phenotype alone. 30 
  31 
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INTRODUCTION 32 
Over the past 30 years the prevalence of obesity has increased markedly with 17% of European 33 
adults(1) and 9% of adults globally now being obese (2). Obesity is a major risk factor for non-34 
communicable diseases (NCDs) including type 2 diabetes (T2D), cardiovascular diseases (CVDs) 35 
and many cancers (3, 4). This emphasizes the importance of initiatives aimed at changing lifestyle 36 
to prevent and to reduce excess body weight (5). Although previous intervention strategies have 37 
mainly focused on “one size fits all” approaches to change dietary and PA behaviors, recent studies 38 
have used personalized approaches, e.g. tailored web-based interventions (6-10). There is mixed 39 
evidence about the effect of personalized interventions compared with conventional interventions 40 
in achieving behavioral changes, but results for weight loss seem promising (11-14). 41 
Reductions in cost and time needed for genome sequencing and enhanced ability to extract relevant 42 
information, e.g. disease risk, have fuelled interest in use of personal genetics to tailor 43 
interventions (15, 16). However, the effectiveness of genetic-based information in facilitating 44 
behavior change is unclear. A recent systematic review called for more, and larger, randomized 45 
controlled trials (RCTs) to determine whether DNA-based advice motivates people to make 46 
appropriate behavioral changes (17). 47 
Variants in the first intron of the fat mass and obesity associated (FTO) gene strongly associated 48 
with development of obesity (10, 18-20). Individuals homozygous for the FTO risk allele AA 49 
(rs9939609) weighed on average 3 kg more and had 1.7-fold increased odds of being obese 50 
compared with those homozygous for the lower-risk allele TT (21). Although there is increasing 51 
evidence that the FTO genetic susceptibility to obesity can be modulated by lifestyle factors such 52 
as physical activity (PA) (10, 22, 23), there is a lack of evidence on whether disclosing information 53 
on FTO genotype would motivate individuals to adopt more healthy lifestyles to reduce weight 54 
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(24). A recent study showed that feedback on FTO risk increased readiness to control weight in 55 
young and healthy adults, but no evidence of actual behavior change was found (25). The current 56 
study is part of the Food4Me intervention trial which was designed to investigate the effectiveness 57 
of different levels of personalised nutrition, including dietary, phenotypic and genotype based 58 
advice, on improving diet and health-related outcomes (14). The genotype based advice within the 59 
Food4Me trial used 5 different genetic variants each associated with a specific nutrient or 60 
phenotypic marker. However, the current study focuses on the effect of disclosing information 61 
about FTO genotype which was the only variant for which personalised advice for weight loss was 62 
provided. Thus, the aim of the present study was to assess the impact of disclosing personalised 63 
FTO based information on changes in obesity-related markers, and to investigate whether changes 64 
in obesity markers were different from those observed in other interventions groups who received 65 
non-genotype based personalised nutrition advice.  66 
 67 
METHODS 68 
Study design 69 
Subjects were participants of the Food4Me Proof-of-Principle Study, a 6-month web-based RCT 70 
on personalized nutrition conducted across 7 European countries (Germany, Greece, Ireland, the 71 
Netherlands, Poland, Spain, and the UK). As outlined elsewhere (26), 1607 adults aged ≥ 18 years 72 
were included in the study. Exclusion criteria included no or limited access to the Internet, 73 
following a prescribed diet or having altered nutritional requirements because of medical 74 
conditions. Participants were screened online between August 2012 and August 2013; the 75 
characteristics of these individuals have been reported elsewhere (27). 76 
Intervention arms 77 
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Full details of the study design have been published elsewhere (26). Briefly, participants were 78 
randomly allocated to one of 4 groups: Level 0: standard, non-personalized dietary and PA 79 
guidelines; Level 1: personalized advice based on current weight, diet and PA; Level 2: 80 
personalized advice based on current weight, diet, PA and phenotype (e.g. waist circumference 81 
[WC], blood cholesterol); and Level 3: personalized advice based on current weight, diet, PA, 82 
phenotype and genotype information for 5 genetic variants (FTO, FADS1, TCF7L2, APOE(ɛ4), 83 
MTHFR). All data were collected remotely (i.e. at home) at baseline, month 3 and month 6 84 
following standardized operating procedures (26). 85 
 86 
Following analysis of data collected at baseline and 3 months, participants received personalized 87 
feedback on their weight, diet and PA (Levels 1-3) or non-personalized guidelines (Level 0), 88 
depending on their randomization group, at both time points. The personalized feedback was based 89 
on pre-defined algorithms incorporating anthropometric, dietary and PA (Levels 1-3), phenotypic 90 
(Levels 2-3), and genotypic (Level 3 only) data. Results in the personalized feedback reports were 91 
indicated for each anthropometric, dietary, PA (Levels 1-3), and phenotypic (Levels 2-3) item, on 92 
3-color graded lines (green, good; amber, improvement recommended; and red, improvement 93 
strongly recommended). In addition, all Level 3 participants received information on whether they 94 
carried the risk variant for 5 nutrition- and lifestyle-related genes (Table 1). The feedback provided 95 
for each of these five genetic variants is described in Table 1 (26). The target nutrients or 96 
phenotypic markers related to these genotypic variants and for which participants received 97 
personalised advice were body weight for the FTO gene, omega 3 fatty acids intake for the FADS1 98 
gene, fat intake for the TCF7L2 gene, saturated fat intake for the APOE(ɛ4) gene, and folate for 99 
the MTHFR gene. However, for the purposes of this study, we have included only those 100 
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participants who received genotype-based advice for the FTO gene, and who were advised to 101 
reduce their body weight (Table 1, Supplemental Figure 1 and 2).  102 
For FTO, the following message was included in reports delivered to Level 3 participants:  103 
“A specific variation of this gene is associated with a greater need to maintain a healthy body 104 
weight and engage in physical activity. A healthy weight combined with exercise may provide 105 
added health benefits for these individuals”, 106 
and Level 3 participants were informed about their FTO rs9939609 status i.e. whether they carried 107 
or not the risk allele (‘yes’ or ‘no,’ respectively). However, this feedback did not include any 108 
numerical information about how much extra weight an individual with a risk-conferring variant 109 
of FTO would be expected to carry (Supplemental Figure 1 and 2). Each personalized report 110 
(Levels 1-3) contained a specific message related to body weight, which, for Level 3 participants 111 
only, referred to FTO. For example, an AA/AT Level 3 participant with increased BMI and WC 112 
would read:  113 
“We recommend reducing your body weight and waist circumference to a healthy normal 114 
range because you have a genetic variation that can benefit by reducing these two obesity-115 
related markers”.  116 
Data collection 117 
Participants consented to self-report their measures via the Internet and to send biological samples 118 
(buccal swabs for DNA extraction) by post, using pre-paid, stamped and addressed envelopes. To 119 
ensure that procedures were similar in all recruiting centres, standardised operating procedures 120 
were prepared for all measurements, and researchers underwent centralised training. Moreover, to 121 
enable participants to collect and report the required information and to collect, process and 122 
dispatch the biological samples correctly, participants were given detailed instructions, and video 123 
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demonstrations were available on the Food4Me website (www.food4me.org), in their own 124 
language (26). 125 
Ethical approval and participant consent 126 
1607 participants were randomized into the study and were recruited between August 2012 and 127 
August 2013 from the following centers: University College Dublin (Ireland), Maastricht 128 
University (The Netherlands), University of Navarra (Spain), Harokopio University (Greece), 129 
University of Reading (United Kingdom, UK), National Food and Nutrition Institute (Poland) and 130 
Technical University of Munich (Germany). The Research Ethics Committees at each University 131 
or Research Centre delivering the intervention granted ethical approval for the study. The 132 
Food4Me trial was registered as a RCT (NCT01530139) at Clinicaltrials.gov. All participants 133 
expressing an interest in the study were asked to sign online consent forms at two stages in the 134 
screening process. These consent forms were automatically directed to the local study investigators 135 
to be counter-signed and archived (26). 136 
Anthropometric and lifestyle measures  137 
Body weight, height and WC were self-measured and self-reported by participants via Internet. 138 
Participants were instructed to measure body weight after an overnight fast, without shoes and 139 
wearing light clothing using a home or commercial scale, and to measure height, barefoot, using a 140 
standardised measuring tape provided by the researchers. WC was measured at the mid-point 141 
between the lower rib and the iliac crest using the provided tape (26). Central obesity was defined 142 
as WC >88 cm for women and >102 cm for men. BMI (kg.m-2) was calculated from body weight 143 
and height. Adiposity status was defined using World Health Organization (WHO) criteria for 144 
BMI (underweight <18.5 kg.m-2, normal weight ≥18.5 kg.m-2 to ≤24.9 kg.m-2, overweight ≥25.0 145 
kg.m-2 to ≤29.9 kg.m-2 and obesity ≥30.0 kg.m-2). Self-reported measurements were validated in a 146 
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sub-sample of the participants across 7 European countries and showed a high degree of reliability 147 
(26). 148 
Physical activity level (PAL, defined as the ratio between total energy expenditure and predicted 149 
basal metabolic rate (28)) and time spent sedentary (min.d-1) were estimated from tri-axial 150 
accelerometers (TracmorD, Philips Consumer Lifestyle, The Netherlands).  151 
Genotyping 152 
Participants collected buccal cell samples at baseline using Isohelix SK-1 DNA buccal swabs and 153 
Isohelix dried-capsules and posted samples to each recruiting centre for shipment to LGC 154 
Genomics (Hertfordshire, United Kingdom). LGC Genomics extracted DNA and genotyped 155 
specific loci using KASPTM genotyping assays to provide bi-allelic scoring of FTO single 156 
nucleotide polymorphisms (SNPs) rs9939609 and rs1121980. These two SNPs showed a high 157 
linkage disequilibrium (r2=0.96) and therefore results for rs1121980 are not reported. No 158 
significant deviation from the Hardy-Weinberg Equilibrium was observed for rs9939609 (χ2=0.51; 159 
P=0.48). 160 
Statistical analyses 161 
In this analysis we included participants with BMI ≥25.0 kg.m-2 and/or high WC (>88 or >102 cm, 162 
for women or men, respectively) at baseline, and for whom FTO genotype data were available, as 163 
well as anthropometrics at month 3 or month 6. These individuals were advised to reduce their 164 
weight and/or WC at baseline (Levels 1-3), or would have been advised to do so (Level 0) if they 165 
had not been in the control group.  166 
Results from descriptive analyses are presented as means and SD for continuous variables or as 167 
percentages for categorical variables. All models were adjusted for baseline outcome value, age, 168 
sex and country. Multiple regression analyses were used to determine significant changes from 169 
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baseline to month 3 and baseline to month 6 for FTO risk (AA/AT) as well as non-risk (TT) 170 
carriers. To answer our first research question (“Does knowledge of FTO genotype influence 171 
changes in body weight and WC in carriers and non-carriers of the FTO risk allele?”), we 172 
compared Level 3 risk and non-risk carriers, for whom FTO genotype was disclosed, using 173 
multiple regression analysis. Our secondary research question (“Is FTO-based personalized advice 174 
more effective at reducing body weight and WC than non-personalized guidelines or, personalized 175 
advice based on diet or diet and phenotype alone?”), was tested using multiple regression, 176 
comparing Level 3 risk carriers (reference group) with changes observed in Level 0, Level 1, and 177 
Level 2.  178 
Multiple imputations by fully conditional specification methods (29) were used to address missing 179 
data for body weight and WC. All statistical analyses were performed using Stata (version 14; 180 
StataCorp, College Station, TX, USA) and significance was set at P<0.05. 181 
 182 
RESULTS 183 
Study participants 184 
A total of 5562 participants were screened online between August 2012 and August 2013; the 185 
characteristics of these individuals have been reported in the supplemental material and elsewhere 186 
(27). The first 1607 volunteers meeting the inclusion criteria were recruited to the RCT and 187 
randomized to one of the four intervention arms (Figure 1) (26). Only participants advised to 188 
reduce their body weight or WC at baseline (Levels 1-3), or controls who would have been advised 189 
to do so if they had not been in Level 0, were included (n=683; Figure 1). Baseline characteristics 190 
of these participants by intervention arm are shown in Table 2. In summary, 51% of the 191 
participants were women, mean age 43.3 (range 18 to 73 years) and mean BMI 29.3 (range 25.0 192 
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to 61.7) kg.m-2. After 3 and 6 months, 10% and 14% of participants randomized to the intervention 193 
were lost to follow-up, respectively (Figure 1). However, intention-to-treat analyses were 194 
performed and therefore missing data for body weight and WC at month 3 and month 6 were 195 
imputed as described in the Methods section.    196 
 197 
Changes in adiposity marker in risk and non risk carriers of the FTO genotype 198 
For the overall cohort, irrespective of intervention arm (Table 3, analyses including all participants 199 
from L0-L3), risk carriers of the FTO genotype (AT/AA, n=491) achieved significantly (P=0.023) 200 
bigger weight reductions (-2.10 kg [95% CI: -2.49 to -1.70]) compared with non risk carriers (TT, 201 
n=192) (-1.19 kg [95% CI: -1.79 to -0.59]) at month 6. Similarly, significant differences (P=0.016) 202 
were observed between FTO genotypes for WC (-3.85 cm vs -2.46 cm for risk and non risk carriers, 203 
respectively). However, no significant differences in changes for either body weight or WC 204 
between carriers and non-carriers of the risk allele were observed at month 3 (Supplemental Table 205 
1).   206 
 207 
Effect of knowledge of FTO genotype on changes in obesity-related markers 208 
These findings are restricted to participants randomized to Level 3 and who received personalised 209 
advice to reduce their body weight and/or WC. At month 3, body weight and WC were reduced 210 
significantly for both risk and non-risk carriers of the FTO gene in Level 3 (Supplemental Table 211 
2). However, there were no significant effects of disclosure of FTO risk on changes in obesity-212 
related markers at month 3 (Supplemental Table 2 and Supplemental Figure 3). Furthermore, 213 
in Level 3, nearly twice as many participants carrying the risk allele lost at least 5% body weight 214 
as non-risk carriers (14.2 and 7.6 %, respectively) (Supplemental Table 2).  215 
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Similarly, body weight and WC were significantly reduced from baseline to month 6 in both risk 216 
and non-risk carriers of the FTO risk allele, who were randomized to Level 3 (Table 3). Moreover, 217 
significant differences were found between Level 3 risk and non-risk carriers of the FTO gene for 218 
each of the obesity-related outcomes; reductions in body weight and WC were almost twice as 219 
large in Level 3 risk carriers (-2.28 kg and -4.34 cm) compared with Level 3 non-risk carriers (-220 
1.19 kg and -1.99 cm) (Table 3). Furthermore, 16.2% of Level 3 non-risk carriers compared with 221 
27.4% of the risk carriers, achieved a weight loss >5% at month 6. Similar results were observed 222 
for WC (Table 4). Although there was no significant interaction between FTO genotype and 223 
intervention arm for body weight (P=0.641) or WC (P=0.523), larger reductions in obesity-related 224 
traits were observed for FTO risk carriers, compared with non-risk carriers, in Levels 0-2 where 225 
participants had no knowledge of their genotype (Figure 2). 226 
 227 
Effect of FTO-based personalized advice on obesity-related markers compared with other 228 
forms of personalization 229 
Significant reductions in WC were observed at month 3 in Levels 0 (-1.67 cm), 1 (-2.10 cm) and 230 
2 (-2.14 cm) participants, who were not stratified by FTO genotype. However, these changes were 231 
lower than those observed for Level 3 risk carriers (-3.47 cm). The WC reduction in Level 3 risk 232 
carriers was significantly greater than for participants in Level 0 (P=0.015), Level 1 (P=0.039) and 233 
for Level 2 (P=0.046) who were not stratified by their FTO genotype. However, none of these 234 
findings remained significant after correction for multiple testing (using P<0.01). Participants in 235 
Levels 0, 1 and 2 also showed significant reductions in weight (Supplemental Table 3). At month 236 
6, there were significant reductions in body weight and WC for participants in all intervention 237 
groups (Table 5).  238 
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 239 
DISCUSSION 240 
Main findings  241 
The main findings of this study were: a) both non-personalized and personalized forms of advice 242 
were effective at reducing body weight and WC after a 6-month intervention and b) compared with 243 
the control group, those in Level 3 who were FTO risk carriers had significantly greater reductions 244 
in body weight (-1.34 vs -2.28 kg, p=0.045) and WC (-2.82 vs -4.34 cm, p=0.046). However, the 245 
magnitude of changes observed in Level 1 and 2, who received non-genetic based personalized 246 
advice, for body weight (-2.08 and -1.96 kg, respectively) and WC (-3.51 and -3.63 cm, 247 
respectively) was similar to those observed in Level 3 FTO risk carriers (p>0.05).  248 
Comparison with other studies 249 
In the last decade, there has been growing interest in tailoring lifestyle interventions using personal 250 
DNA information (30). It has been hypothesized that providing lifestyle advice based on genetic 251 
information would motivate people to make behavioral changes favorable for disease prevention, 252 
beyond what could be achieved with non-gene-based tailored programs. In a recent meta-analysis, 253 
Hollands et al.,(31) reported no effect of adding DNA-based disease risk estimates compared with 254 
a non-DNA based approach for interventions aiming at smoking cessation (six studies; n=2663), 255 
improving diet (seven studies; n=1784), and increasing physical activity (six studies; n=1704). The 256 
authors concluded that evidence supporting gene-based interventions for behavior change is 257 
lacking. Existing data come from studies with predominantly high or unclear risk of bias, and 258 
where the evidence was typically of low quality. Therefore, larger and better quality studies should 259 
be performed to elucidate the effect of personalized advice based on genetic information (31).  260 
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The evidence in favor of gene-based lifestyle advice is limited. Arkadianos et al. reported that 261 
participants in a traditional weight management diet group and participants receiving a 262 
nutrigenetically tailored diet both lost similar amounts of weight at 100-300 days of follow up. 263 
Thereafter, participants in the nutrigenetic group were significantly more likely to maintain their 264 
weight loss compared with the control group (32). In contrast, there were no short-term (~3 265 
months) or longer-term (~1 year) changes in self-reported anxiety, or exercise, in generally healthy 266 
adults receiving information from a commercial direct-to-consumer genome-wide risk test (33, 267 
34). However, this study reported changes in fat intake for those individuals who received 268 
increased obesity risk feedback (33). Frankwich and colleagues observed no between-group 269 
differences in weight loss in a small study of American veterans randomly assigned either to a 270 
genetics-guided therapy group, where participants received one of four diets (balanced, low-271 
carbohydrate, low-fat or Mediterranean) based on their risk status for seven obesity-related SNPs 272 
(APOA2, ADIPOQ, FTO, KCTD10, LIPC, MMAB and PPARG), or to a standard therapy group, 273 
where participants followed a balanced diet (35). Furthermore, Meisel et al. showed that healthy 274 
individuals receiving feedback on  FTO status in their weight control advice felt more prepared to 275 
control their weight but this had no greater effect on behavior than weight control advice alone 276 
(25). Our results are in line with studies outlined above. We observed that the magnitude of weight 277 
and WC reductions was similar in all three groups receiving personalized advice; adding gene-278 
based advice did not seem to promote adiposity changes beyond what was achieved by tailored 279 
feedback based on diet or diet and phenotype alone. 280 
Although differences in weight and WC reductions were almost twice as large in individuals 281 
informed of their risk for FTO, compared with those informed of their absence of FTO-related 282 
risk, there was no clear evidence that risk knowledge played a role. Surprisingly, FTO risk carriers, 283 
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irrespective of their intervention group, had greater improvements in obesity-related markers than 284 
non-risk carriers. This was an unexpected and rather counter-intuitive finding. All other factors 285 
being equal (same environment), one would expect that individuals who are genetically (and/or 286 
epigenetically) predisposed to obesity would have to make greater efforts to counter this 287 
predisposition and to achieve similar weight loss as other obese individuals who are not genetically 288 
predisposed. Alternatively, the fact that carriers of the FTO risk allele were slightly heavier than 289 
non-risk carriers may mean that they have greater motivation to lose weight when compared with 290 
participants with no copies of the FTO risk variant, who were lighter at baseline. For example, in 291 
a relatively small study of 51 obese or overweight U.S. veterans, Frankwich and colleagues 292 
observed that participants who had low-risk polymorphisms for obesity lost more weight than all 293 
other participants at 8 weeks and had significantly greater reductions in BMI and WC at 24 weeks 294 
(35). However, these finding are in disagreement with a recent meta-analysis conducted using 295 
9563 individual participant data from eight randomized controlled trials. This study found that the 296 
FTO genotype had no detectable effect on weight loss in overweight and obese adults in response 297 
to lifestyle or drug-based intervention (36).  298 
 299 
Strengths and limitations 300 
The Food4Me study is the largest Internet-based intervention on personalized nutrition to date. 301 
Innovative aspects of the Food4Me Study include the creation of algorithms for delivering tailored 302 
lifestyle advice based on participant characteristics including behavioral, phenotypic and 303 
genotypic information. Another strength of the study was the delivery of the intervention across 7 304 
European countries via the Internet and application of a remote system for data and biological 305 
sample collection. Our Internet-based platform was effective in retaining participants; 85% 306 
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completed month 6 follow up and there was > 98% compliance with DNA testing, which is high 307 
compared with previous web-based survey research (37) and web-based (34) or face-to-face (25) 308 
genetic-based interventions. In a study of direct-to-consumer genomic testing, Bloss et al. reported 309 
44% and 63% dropouts at months 3 and 12, respectively (33, 34). Moreover, the profile of those 310 
interested in participating in the Food4Me intervention study was similar to that of European adults 311 
(26), most of whom would benefit from improved diet and more PA. Finally, we used multiple 312 
imputation procedures to address missing data and so maximized the amount of useful information 313 
available from the 683 participants in the part of the Food4Me Study. 314 
Our limitations include that we did not investigate how participants perceived the DNA-based 315 
feedback. Given that Food4Me was an intervention targeting multiple, dietary and lifestyle 316 
behaviors, the impact of the genotypic results might have been diluted by the volume of other 317 
information provided. Moreover, the genetic feedback was “only” a positive reinforcement, i.e. 318 
that participants with the higher-risk genotype would benefit more by reducing their weight and 319 
WC. The greater risk for obesity and associated co-morbidities was not stressed in the reports and 320 
it is possible that the impact of such feedback would have been stronger. Additionally, some of the 321 
analyses performed by intervention arm and FTO genotype in this investigation of secondary 322 
outcomes may not have the statistical power to detect biologically/ clinically-relevant differences 323 
in adiposity. Larger studies are needed to corroborate these findings. Finally, height, weight, and 324 
WC were self-reported but a concurrent validation study showed that the self-reported 325 
anthropometric measures were reliable (38).   326 
Conclusion  327 
Larger reductions in body weight and WC were observed for risk carriers compared with non-risk 328 
carriers of the FTO gene. However, changes in these obesity-related traits were similar in all 329 
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groups receiving personalized advice. Adding genetic information to the tailored feedback did not 330 
enhance the effectiveness of the intervention, compared with personalization based on diet or diet 331 
and phenotype alone. Our personalized Internet-based intervention was effective at recruiting and 332 
retaining participants. This offers promise as a scalable and sustainable route to improve behaviors 333 
with important public health benefits (11).   334 
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Table 1. Genetic feedback delivered to participants randomized to Level 31  
Genes Targeted 
recommendation 
Nutritional influences associated with some 
variations of this gene 
Do you have 
the genetic 
variation that 
can be 
modified by 
dietary 
change? 
FTO  
 
Reduce body 
weight 
A specific variation of this gene is associated 
with a greater need to maintain a healthy body 
weight and engage in physical activity. A healthy 
weight combined with exercise may provide 
added health benefits for these individuals.   
Yes / No 
FADS1  Increase Omega 3 
intake 
People with a specific variation of this gene can 
benefit by increasing their intake of the healthy 
omega-3 fat found in oily fish. Increasing 
omega-3 intake has been associated with an 
improvement in factors relating to cardiovascular 
health in these individuals. 
Yes / No 
TCF7L2 Reduce fat intake A specific variation of this gene is associated 
with improved weight loss when following a low 
fat diet compared to other weight loss diets. 
Reducing dietary fat may enhance weight loss in 
these individuals. 
Yes / No 
ApoE(e4) Reduce saturated 
fat intake 
A specific variation of this gene is associated 
with a greater need to maintain healthy 
cholesterol levels. Decreasing saturated fat 
intake has been associated with an improvement 
in cholesterol and factors relating to 
cardiovascular health in these individuals.  
Yes / No 
MTHFR Increase folate 
intake 
People with a specific variation of this gene can 
benefit by increasing their intake of the vitamin 
folate. Increasing folate intake (found in green 
leafy vegetables) has been associated with an 
improvement in factors relating to cardiovascular 
health in these individuals. 
Yes / No 
 1Genetic information provided to participants randomized to the “Level 3” and who received 
personalised advice based on diet, phenotypic markers and these genetic markers.  
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Table 2. Baseline characteristics of the Food4Me participants with high BMI or WC by intervention arm1 
 Level 1 
“Control” 
 
Level 1 
“Diet” 
 
Level 2 
“Diet + 
Phenotype” 
Level 3  
FTO Non-risk 
(TT) 
Level 3  
FTO Risk 
(AT/AA) 
Total (n) BMI ≥25.0 kg.m-2 171 153 173 47 139 
Total (n) WC >88 or >102 cm 
for women and men respectively 
84 82 96 27 71 
Sex - women (%)  53.8 49.0 47.4 48.9 54.6 
Age (years) 42.9 (12.2) 44.2 (11.4) 43.9 (12.1) 42.2 (13.3) 43.7 (11.9) 
Anthropometrics      
Weight (kg) 85.1 (12.6) 87.5 (15.0) 87.3 (12.8) 83.9 (12.4) 86.1 (12.9) 
BMI (kg.m-2) 29.0 (3.8) 29.7 (4.5) 29.8 (3.9) 28.7 (3.1) 29.4 (4.3) 
WC (cm) 95.7 (11.1) 96.0 (0.12) 96.9 (11.6) 94.2 (10.8) 96.1 (11.0) 
Physical Activity      
PAL2 1.69 (0.13) 1.72 (0.16) 1.70 (0.16) 1.71 (0.13) 1.69 (0.13) 
Sedentary time (min.day-1) 761.9 (77.5) 761.9 (73.9) 761.0 (84.2) 756.5 (74.7) 767.7 (79.4) 
1Level 0 received non-personalized advice. Levels 1, 2, and 3 received personalized advice based on Diet, Diet + Phenotype, or Diet + Phenotype + Genotype, respectively. Baseline 
characteristics for all interventions arms include only participants with a BMI ≥25.0 and/or WC >88 cm and >102 cm for women and men, respectively.  
2PAL, physical activity level (ratio between total energy expenditure and basal metabolic rate);  
Celis-Morales CA - AJCN. First published ahead of print April 5, 2017 as doi: 10.3945/ajcn.116.145680. 
 
 
Table 3. Changes in obesity-related markers at month 6 in risk and non-risk carriers of the 
FTO genotype1  
 FTO  
non-risk (TT) 
 
FTO risk  
(AT/AA) 
 
P-value for 
difference in change 
between risk and 
non-risk carriers 
Analysis including participants 
from L0-L32 
   
Weight (kg)    
   n 192 491  
   Delta -1.19* -2.10* P=0.023 
   (95% CI) (-1.79, -0.59) (-2.49; -1.70)  
WC (cm)    
   n 107 252  
   Delta -2.46* -3.85 * P=0.016 
   (95% CI) (-3.40, -1.51) (-4.49; -3.21)  
Analysis restricted to 
participants in L33 
   
Weight (kg)    
   n 47 139  
   Delta -1.19* -2.28* P=0.037 
   (95% CI) (-2.19, -0.19) (-3.06, -1.48)  
WC (cm)     
   n 27 71  
   Delta -1.99* -4.34* P=0.048 
   (95% CI) (-4.04, -0.05) (-5.63, -3.08)  
1Data presented as delta and 95% confidence interval. Significant changes between baseline and month 6: *P<0.01; Models were 
adjusted for country, age, sex, and baseline outcome measures. Intervention arm was included as an additional covariate in the 
analysis. Deltas were calculated as [month 6 – baseline]. 2These analyses pooled participants from all interventions groups (control, 
L1, L2 and L3) who were advised to loss body weight or to reduce their WC, irrespective of whether they were informed or not of 
their genetic risk. 3These analyses were restricted to those participants randomized to Level 3 and who were informed of their FTO 
genotype (risk or non risk) and who were advised to loss body weight or reduce their WC. Significant changes in the outcomes 
from baseline were tested using multiple regression analysis. Differences in the outcomes delta between risk and non-risk carriers 
were tested using regression analysis.  
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Table 4. Percentage of participants who achieved 2.5%, 5% and 10% weight loss or waist 
circumference (WC) reduction by intervention arm at month 61 
 Level 1 
“Control” 
 
Level 1 
“Diet” 
 
Level 2 
“Diet + 
Phenotype” 
Level 3 
FTO non risk 
(TT) 
Level 3 
FTO risk 
(AT/AA) 
Weight (kg)      
n 171 153 173 47 139 
2.5% to 4.9% 20.5  20.4 15.4 21.6 21.7 
5.0% to 9.9% 13.0 11.8 18.8 16.2 21.8 
≥10% 4.8 8.7 4.0 0 5.6 
WC (cm)      
n 84 82 96 27 71 
2.5% to 4.9% 20.0 16.7 24.2 13.5 16.3 
5.0% to 9.9% 14.5 16.7 24.2 13.5 22.6 
≥10% 6.2 9.5 6.8 2.7 8.1 
1Data presented as percentages. No formal comparisons between groups were made for results presented in this table. These 
analyses were restricted to participants who were advised to lose body weight or to reduce their WC.  
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Table 5. Changes in obesity-related markers at month 6 in Level 3 (FTO risk and non risk carriers) compared with 
participants in Levels 0, 1 or 2 who did not receive genotype advice1 
 Intervention arms P-value 
 Level 0 
“Control 
group” 
 
Level 1 
“Diet” 
 
Level 2 
“Diet + 
Phenotype” 
 
Level 3 
FTO non risk 
(TT) 
Level 3 
FTO risk 
(AT/AA)  
L3 FTO 
risk vs 
Control 
 
L3 FTO 
risk vs 
L1 
 
L3 FTO 
risk vs  
L2 
Weight (kg)         
   n 171 153 173 47 139    
   Delta -1.34  -2.08 -1.96 -1.19 -2.28  0.045 0.752 0.602 
   (95% CI) (-2.02, -0.66)* (-2.83, -1.31)* (-2.54, -1.37)* (-2.19, -0.19)* (-3.06, -1.48)*    
WC (cm)         
   n 84 82 96 27 71    
   Delta -2.82 -3.51 -3.63 -1.99 -4.34  0.046 0.290 0.361 
   (95% CI) (-3.86, -1.78)* (-4.82, -2.21)* (-4.54, -2.72)* (-4.04, -0.05)* (-5.63, -3.08)*    
1Data presented as delta and 95% confidence interval. Significant changes between baseline and month 6: *P<0.001. The p-value was corrected for multiple testing and significant 
differences were set as p<0.01. Models were adjusted for country, age, sex, and baseline outcome measures. Deltas were calculated as [month 6 – baseline]. Significant changes in 
the outcomes from baseline and differences within the each level were tested using multiple regression analysis. These analyses were restricted to participants in Levels 0, 1 and 2 
who were advised to lose body weight and/or to reduce their WC and who were not stratified by FTO genotype for comparison with participants in Level 3 who were further stratified 
as FTO risk and non risk carriers.   
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Figure 1. CONSORT diagram 
BMI, body mass index; WC, waist circumference. Participants in Level 0 received non-personalized advice, whereas participants 
in Levels 1-3 received personalized advice, during the intervention. Participants in Levels 1-3 with high BMI (≥25 kg.m-2) or WC 
(>88 or 102 cm for women or men, respectively) at baseline were advised to reduce their body weight. For analyses, Level 3 was 
stratified based on FTO genotype (TT: non-risk and AA, AT: risk).    
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Figure 2. Changes in obesity-related markers at month 6 by intervention arm and FTO 
genotype 
Data are presented as mean delta from baseline and 95% confidence interval. Non risk and risk carriers across all intervention 
Levels reduced their waist circumference at month 6 compared with month 0 (P<0.001). Similar reductions were observed for 
body weight except for non risk carriers in Levels 0 and 1. No significant interactions were observed between intervention arm 
and FTO genotype for any of the outcomes. Analyses were adjusted for age, sex, country and outcome values at baseline. WC, 
waist circumference. The interaction between intervention arm and FTO genotype was tested using regression analysis (P=0.641 
and P=0.523 for body weight and WC, respectively). Participants included in the analysis were restricted to those advised to 
reduce their body weight and/or WC. Numbers of participants included for body weight non risk and risk carriers, respectively, 
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were L0 n=46’ 124; L1 n=50, 101; L2 n=48, 125; L3 n=47, 139. Numbers for WC non risk and risk carriers, respectively, were 
L0 n=24, 59; L1 n=28, 54, L2 n=28, 68; L3 n=27, 71. 
